Soleno Therapeutics (SLNO) Research & Development (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Research & Development data on file, last reported at $11.3 million in Q1 2026.

• On a quarterly basis, Research & Development fell 16.59% year-over-year to $11.3 million in Q1 2026; TTM through Mar 2026 was $38.4 million, a 50.46% decrease from a year earlier, with the FY2025 full-year figure at $40.6 million, down 48.29% from the prior year.
• Research & Development for Q1 2026 stood at $11.3 million, up from $9.6 million in the prior quarter.
• Over the last five years, Research & Development for SLNO reached as high as $30.1 million in Q3 2024 and fell as low as $3.7 million in Q2 2022.
• Historically, Research & Development has averaged $10.1 million across 5 years, with a median of $8.7 million in 2023.
• Across the five-year window, Research & Development surged 398.73% in 2024 and sank 72.11% in 2025, its largest moves.
• Year by year, Research & Development stood at $3.8 million in 2022, then soared by 128.06% to $8.7 million in 2023, then soared by 147.28% to $21.5 million in 2024, then plunged by 55.52% to $9.6 million in 2025, then increased by 17.95% to $11.3 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $11.3 million in Q1 2026, $9.6 million in Q4 2025, and $8.4 million in Q3 2025.